Vanda Pharmaceuticals (VNDA) Enterprise Value (2010 - 2026)

Vanda Pharmaceuticals has reported Enterprise Value for 17 years, with the latest figure at -$202.3 million in Q1 2026.

• Quarterly Enterprise Value rose 40.66% year-over-year to -$202.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.3 million (up 40.66% YoY) and the FY2025 annual result came in at -$263.8 million, up 29.57% from the prior year.
• Enterprise Value advanced to -$202.3 million in Q1 2026 per VNDA's latest filing, from -$263.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$202.3 million in Q1 2026 and troughed at -$501.5 million in Q1 2023.
• A 5-year average of -$389.7 million and a median of -$388.3 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2023 and 2026: Enterprise Value retreated 15.24% in 2023, then soared 40.66% in 2026.
• Over 5 years, Enterprise Value stood at -$466.9 million in 2022, then increased by 16.83% to -$388.3 million in 2023, then rose by 3.51% to -$374.6 million in 2024, then increased by 29.57% to -$263.8 million in 2025, then rose by 23.32% to -$202.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$202.3 million, -$263.8 million, and -$293.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.